<
/p>
Disclosures: Dr. Saraf has no ACCME d
efined commercial interests. His presentation will be evidence based and
free of bias.
Lecture 1. The Choroid: The Final Frontier <
/p>
After participating in
this activity, attendees should be able to:
1.Ide
ntify conditions in retina and uveitis where extended evaluation of the cho
roid may be of clinical utility.
2. Interpret the testing modalities used to assess
the choroid, including enhanced depth imaging optical coherence tomography
(OCT), indocyanine angiography, OCT angiography, and choroidal vascularity
index (CVI).
3. Describe the features of pachycormi
d spectrum disorders.
4. Utilize testing mo
dalities to assess choroidal neovascularization and distinguish subclinical
choroidal neovascularization from clinically active choroidal neovasculari
zation.
Lecture 2. Ocular Complications of Novel Cancer Therapies
Learning objectives:
After participating in this activity, atten
dees should be able to:
1. Understand t
he mechanism of action of novel cancer therapies (immunotherapy, targeted t
herapy) and the impact of these agents on systemic health and patient survi
val.
2.Recall characteristic manifestations of novel cancer therapies when a
dversely affecting the eye.
3. Identify strategies to manage ocular side effects whi
le maximizing systemic benefit for patients on these agents.
<
/span>
DTSTAMP:20240329T102852
DTSTART;TZID=America/Los_Angeles:20201216T183000
DTEND;TZID=America/Los_Angeles:20201216T203000
SEQUENCE:0
TRANSP:OPAQUE
END:VEVENT
END:VCALENDAR